Lupin’s marketing authorization application (MAA) for biosimilar Etanercept has been accepted for review by Europe drug regulator, European Medicines Agency (EMA).

MAA means an application submitted by a drug manufacturer seeking permission, from the regulator to sell the drug. Etanercept is suggested for treating Rheumatoid Arthritis (RA), Psoriatic Arthritis, Ankylosing Spondylitis, Axial spondyloarthritis, Non-radiographic axial spondyloarthritis and Plaque Psoriasis.

Furthermore, Lupin’s MD Nilesh Gupta stated, “The application for our Etanercept biosimilar and its acceptance in Europe is a significant milestone for our foray into biosimilars in key developed markets. This is also an encouraging development as we continue building our pipeline of higher complexity products.”

Read EquityPandit’s Technical Analysis of Lupin